Taro drug gets tentative approval for fungal infections treatment
-
- March
- 27
Taro Pharmaceutical Industries Ltd., an Israel-based company with operations in Hawthorne, said this morning that it has gotten tentative federal approval for a product that treats fungal infections of the nails.
The U.S. Food and Drug Administration has determined that Ciclopirox is safe and effective compared with a product made by Sanofi-Aventi Pharmaceuticals. That product has annual sales in the United States of $88 million, Taro said.
Taro said the approval means it can market the product when patents and other restrictions expire, which is expected to happen in September.
Taro shares closed yesterday at $8.50, down 5 cents.
This entry was posted
on Tuesday, March 27th, 2007 at 12:03 pm by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
